Repligen on track for NDA filing for MRI pancreas agent, seeking priority review
This article was originally published in Scrip
Executive Summary
Repligen's shares got a slight bump from the news that the company intends to submit its new drug application (NDA) later this summer on schedule for RG1068, a synthetic version of human secretin, as an agent to improve MRIs of the pancreas, with plans to seek a six-month priority review from the US FDA.